Research demonstrates the potential of the Parsortix® system to support powerful characterisation of CTCs in head and neck cancer.
Category: Uncategorized
Come see us at the 6th ACTC meeting 2023
Visit us to experience the power of the Parsortix® PC1 system, our unique FDA cleared, and CE marked circulating tumor cell (CTC) enrichment technology.
Why CTCs and liquid biopsies could one day revolutionise NHS cancer care
The article is part of the Supporting the NHS Campaign 2023 and focuses on how new innovations could improve patient outcomes and support the NHS.
New publication!
Parsortix® system outperforms current laboratory standard for disseminated tumour cell (DTC) harvest.